The Exploration of OX40 (CD134) Expression Levels in Sarcoma Specimens and Its Clinical Application in Prognosis Determination

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Total Enrollment

200 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-01-01

Study Completion Date

2026-10-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study aims to investigate the expression of OX40 (CD134) in sarcomas and its impact on prognosis, with the goal of identifying novel biomarkers for early resistance detection and optimizing treatment strategies for sarcoma patients. Sarcomas are a highly heterogeneous group of malignant tumors, for which current treatment options are often suboptimal in certain patients, and effective biomarkers to guide therapy are lacking. As a T-cell costimulatory receptor, OX40 plays a significant role in immune regulation across various solid tumors and holds promise as a potential therapeutic target.

The researcher's team has previously identified high OX40 expression in sarcomas through database analysis and validated the therapeutic efficacy of antibody-drug conjugates targeting OX40 in in vivo experiments using sarcoma cell lines in murine models. This study will evaluate the mRNA expression levels of OX40 in tumor tissues from sarcoma patients and assess OX40 protein expression using immunohistochemical staining. By integrating these findings with clinical and pathological data, the study will explore the potential of OX40 expression levels in tumor tissues as biomarkers for predicting treatment response and prognosis in primary bone tumors. The results aim to provide scientific evidence for the clinical application of OX40-targeted therapies and to propose novel therapeutic strategies to improve survival outcomes in sarcoma patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

PD-L1 Expression in Advanced Osteosarcoma

NCT03582527

Progression Survival

UNKNOWN

Study of Biomarker From Blood and Tissue of Head and Neck Carcinoma

NCT01171235

Laryngeal Neoplasms Pharyngeal Neoplasms

UNKNOWN

Exploring the Expression Level of Cadherin 6 Protein (CDH6) in Primary Malignant Bone Tumor Specimens and Its Clinical Application in Prognosis Assessment

NCT06850506

Sarcoma Sarcoma, Bone Ewing Sarcoma +1 more

ACTIVE_NOT_RECRUITING

The Detection of Circulating Tumor Cells (CTCs) in Patients With Lung Cancer Undergoing Cryosurgery Combined With DC-CIK Treatment

NCT02412384

Neoplastic Cells, Circulating

COMPLETED

Prediction of Response to PD-L1 Inhibitor After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer Using Multi-omics-based Liquid Biopsy

NCT06869239

Limited-stage Small Cell Lung Cancer (LS-SCLC)

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sarcoma Biomarkers Progression

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

OX40 (CD134) expression levels of sarcoma specimens in treatment-native sarcoma patients

Before delivering neoadjuvant chemotherapy, using IHC to test the protein expression of OX40 and using RNA-seq to test the RNA of OX40

IHC: Immunohistochemistry

Intervention Type DIAGNOSTIC_TEST

Immunohistochemistry will be implied in tissue sections to test the expression of OX4O in sarcoma.

RNA-seq

Intervention Type GENETIC

RNA-seq will be implied in tissue sections to test the expression of CD134 RNA expression in sarcoma.

OX40 (CD134) expression levels of sarcoma specimens in chemotherapy treated sarcoma patients

After neoadiuyant chemotherapy, using IHC to test the protein expression of OX40 and using RNA-seq to test the RNA of OX40

IHC: Immunohistochemistry

Intervention Type DIAGNOSTIC_TEST

Immunohistochemistry will be implied in tissue sections to test the expression of OX4O in sarcoma.

RNA-seq

Intervention Type GENETIC

RNA-seq will be implied in tissue sections to test the expression of CD134 RNA expression in sarcoma.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

IHC: Immunohistochemistry

Immunohistochemistry will be implied in tissue sections to test the expression of OX4O in sarcoma.

Intervention Type DIAGNOSTIC_TEST

RNA-seq

RNA-seq will be implied in tissue sections to test the expression of CD134 RNA expression in sarcoma.

Intervention Type GENETIC

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Aged 8 years or older.
* Diagnosed with high-grade osteosarcoma or Ewing sarcoma, confirmed through clinical evaluation or histopathological examination. For patients with localized tumors or solitary pulmonary lesions, pathological confirmation is required; for patients with multiple pulmonary metastases, pathological examination is not necessary.
* Treatment-naïve patients who have not received standard first-line chemotherapy regimens for osteosarcoma or Ewing sarcoma.(First-line chemotherapy drugs include high-dose methotrexate, anthracyclines, cisplatin, and ifosfamide. For Ewing sarcoma, the standard first-line regimen is VDC followed by IE.)
* All other examination indicators suggest that the patient is eligible for standardized chemotherapy and surgical treatment for bone tumors.

Exclusion Criteria

* Inability to undergo standardized chemotherapy and surgical treatment for bone tumors at this center.
* Refusal to adhere to follow-up according to standardized diagnostic and treatment protocols.
* Any condition that, in the investigator's opinion, may harm the participant or prevent them from meeting or complying with the study requirements.

Minimum Eligible Age

8 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No